An Open-Label, Randomized, Single-Dose, Two-Way Crossover Bioequivalence Study Of 8 Mg Fesoterodine Extended-Release Tablets (Toviaz), Manufactured At Zwickau Versus Vega Baja, In Healthy Subjects.

Trial Profile

An Open-Label, Randomized, Single-Dose, Two-Way Crossover Bioequivalence Study Of 8 Mg Fesoterodine Extended-Release Tablets (Toviaz), Manufactured At Zwickau Versus Vega Baja, In Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Dec 2013

At a glance

  • Drugs Fesoterodine (Primary)
  • Indications Overactive bladder
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 06 Jul 2012 New source identified and integrated (German Clinical Trials Register: DRKS00003982).
    • 31 May 2011 Actual end date changed from Jul 2009 to Aug 2009 as reported by ClinicalTrials.gov.
    • 09 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top